



GENE EXPRESSION



Each successive boundary represents a 2-fold difference in expression, i.e. 2X, 4X, 8X

IMMUNE PROFILE



GENE EXPRESSION FULL RESULTS

Gene Name	TPM for Reference	TPM for Sample	Fold Change (log ₂)	P-value	Significance
PD-1	70.000	0.640	-6.784	0.000	***
PD-L1	39.620	7.620	-2.379	0.200	
CTLA4	32.460	1.770	-4.194	0.049	*
OX40	69.260	2.340	-4.887	0.003	**
TIM-3	3.810	61.130	4.004	0.003	**
BTLA	17.710	986.710	5.800	0.000	***
ICOS	14.130	2.690	-2.393	0.239	
CD47	65.450	1047.200	4.000	0.120	
IDO1	103.880	5.350	-4.278	0.070	
ARG1	0.200	17.560	6.484	0.000	***

IMMUNE PROFILE FULL RESULTS

Cell Type	Percentage
CD4+ T Cells	7
CD8+ T Cells	44
CD19+ B Cells	13
CD14+ Monocytes	5
CD56+ NK Cells	15
M1 Macrophages	6
M2 Macrophages	8
Treg Cells	2

STATEMENT OF PERFORMANCE

The ImmunoPrism assay was developed and characterized by Cofactor Genomics in San Francisco, CA. ImmunoPrism is for Research Use Only and not for use in diagnostics procedures. The results of the included report are generated by ImmunoPrism Version 1.4.0 and are subject to change in future releases. Expression levels of escape genes are calculated for the sample in comparison to mean expression of a specific cancer. Immune profiling in ImmunoPrism has been shown to significantly correlate with flow cytometry measurements for PBMC samples across 8 different immune cell types. In addition, ImmunoPrism immune profiling performs consistently across fresh-frozen and formalin-fixed samples. Furthermore, ImmunoPrism immune profiling has been validated in dissociated tumor cells. For technical support or additional information on assay performance or validation, please contact: support@cofactorgenomics.com.